Bayer Highlights Cell and Gene Therapy Commitment with US$4 B Asklepios Buyout

By Ashish Tripathi & Michelle Liu

Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)

Published: 18 Dec-2020

DOI: 10.3833/pdr.v2020.i12.2581     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a move to bolster its cell and gene therapy portfolio, Bayer has acquired Asklepios BioPharmaceuticals (AskBio), a company focused on the treatment of neuromuscular and cardiovascular system diseases with gene therapy...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details